Somerset, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in AI-driven healthcare technology solutions for medical practices and health systems nationwide, announced today that its Co-Chief Executive Officers have been invited to participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow,” presented by Maxim Group LLC. The Healthcare IT Panel, featuring CareCloud, will take place on Tuesday, June 3, 202 ...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today that it is planning to invest in two infill development projects for the construction of an estimated 120 residential rental suites on excess land in Mississauga, Ontario (the “GTA Development Projects”). Additionally, CAPREIT is underway with the conversion of certain underutilized non-residential spaces identified throughout its current apartment portfolio for the ...

Core Insights - Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing systemic oncolytic targeted immunotherapies, with its lead candidate CLD-401 presented at the ASCO Annual Meeting [1][2] Group 1: Technology and Innovation - Calidi has developed an enveloped form of its proprietary oncolytic virus that shows greater resistance to immune clearance, enhancing systemic delivery and efficacy in pre-clinical models [2] - The novel genetic modification in CLD-401 incorporates a chimeric CD55 receptor into the virus envelope, which inhibits complement-mediated clearance, improving the virus's stability in circulation [2][4] - The RedTail platform allows for the delivery of genetic payloads directly into the tumor microenvironment, with CLD-401 expressing an IL-15 superagonist to activate and expand natural killer (NK) cells and CD8+ T cells [3][4] Group 2: Strategic Development - Calidi is conducting IND-enabling studies for CLD-401 and plans to submit an Investigational New Drug (IND) application in the second half of 2026 [4] - The company is actively seeking strategic partnerships to accelerate clinical development and enhance the impact of its RedTail platform [4][6] - The lead candidate targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical needs [7]

LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Bitmine Immersion Technologies, Inc. (OTCQX: BMNRD) (“Bitmine” or “Company”), a technology company focused on Bitcoin mining using immersion technology, today announced that it expects its shares of common stock to be approved for listing on the NYSE American LLC stock exchange (“NYSE American”). The Company expects that its common stock will begin trading on the NYSE American under the symbol, “BMNR,” at the opening of trading on or about June 5, 2025, subject t ...

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF), is pleased to announce that Mr. Michael Mulberry has been appointed to the board of directors of the Company. Mr. Mulberry has also been appointed as an independent member of the Audit Committee. Mr. Todd Hanas will be stepping down from his position as a board member, and the Company wishes him well in his future endeavors. Mr. Mulberry, former Director and CE ...

Patent Strengthens AquaRefining™ IP Portfolio and Supports Licensing and Joint Venture Strategy for Global ExpansionRENO, Nev., June 02, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/584,975. The newly allowed patent covers critical aspects of Aqua Metals’ proprietary lithium battery recycling technology ...

TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patient has been enrolled in its new Phase 2 clinical trial protocol of stenoparib for the treatment of advanced, platinum-resistant or platinum-ineligible ovarian cancer. The newly launched protocol will accelerate the clinical d ...

Core Points - The Company announced a monthly distribution of $0.08 per share for June 2025, payable on June 30, 2025 [1] - Future distributions are subject to Board approval and compliance with debt covenants and preferred stock terms [2] - The Company is a non-diversified, closed-end management investment company focused on providing high after-tax total returns through cash distributions [3] - The Company invests at least 80% of its total assets in securities of Energy Infrastructure Companies [3] - Distribution amounts may vary based on portfolio changes and market conditions [4] Distribution Details - Record Date: June 13, 2025 - Payment Date: June 30, 2025 - Distribution Amount: $0.08 - Estimated Return of Capital: 50% [3]

Core Viewpoint - Solar Alliance Energy Inc. reported a decline in revenue for Q1 2025 due to severe weather conditions affecting project timelines, but remains optimistic about future growth in the commercial solar sector [2][3]. Financial Performance - Revenue for Q1 2025 was $835,609, down from $1,604,326 in Q1 2024, reflecting a decrease of approximately 48% [3][7]. - Cost of sales for Q1 2025 was $882,092, compared to $1,014,394 in Q1 2024, resulting in a gross deficit of $46,483, a significant decline from a profit of $585,932 in the previous year [7]. - The net deficit for Q1 2025 was $474,277, contrasting with a net income of $141,303 in Q1 2024 [7]. - Total expenses for Q1 2025 were $424,065, slightly down from $451,188 in Q1 2024 [7]. - The company reported a cash balance of $13,111 as of March 31, 2025 [7]. Business Operations and Strategy - The primary activity in Q1 2025 involved the construction of a large solar project in Kentucky, which faced delays due to severe weather [3]. - The company continues to target larger customers for solar system sales and installations, focusing on utility and commercial sectors, with projects up to 5MWs [5]. - Solar Alliance is committed to servicing small and medium-sized businesses in rural communities while pursuing larger commercial and community solar projects [6]. - The company aims for full-year profitability in 2025, emphasizing opportunities in the Southeast U.S. commercial solar sector [3][6]. Growth Opportunities - Solar Alliance is exploring corporate growth opportunities through partnerships, joint ventures, and other initiatives that align with its profitability and market opportunity criteria [7].

Core Viewpoint - Teck Resources Limited announced mechanical issues at its Carmen de Andacollo (CdA) Operations in Chile, leading to a maintenance shutdown of the SAG mill, but does not expect a material impact on production or sales for 2025 [1][2][3]. Group 1: Production Impact - Production at CdA will be interrupted for approximately one month for repairs, but the company plans to reschedule other maintenance to mitigate the impact [2]. - The previously disclosed guidance for 2025 total annual copper production and for CdA remains unchanged despite the downtime [2]. - An unrelated temporary outage of the shiploader at the Quebrada Blanca (QB) port facility is also expected to last about one month, but operations at the QB mine and plant continue normally [3]. Group 2: Company Overview - Teck is a leading Canadian resource company focused on providing essential metals for economic development and energy transition, with a strong portfolio of copper and zinc operations across North and South America [7]. - The company emphasizes responsible growth and resilience built on stakeholder trust, with shares listed on both the Toronto Stock Exchange and the New York Stock Exchange [7].